Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Urinary Tract Infection
Interventions: Cranberry powder capsules, Placebo powder capsules; Drug
Lead sponsor: Betsy Foxman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions: Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention; Other · Behavioral
Lead sponsor: Hospital de Clinicas de Porto Alegre; Other
Eligibility: 7 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multifocal Motor Neuropathy
Interventions: Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more

Conditions: Patients With Acute Pancreatitis
Interventions: Dexamethasone acetate, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Inflammation
Interventions: Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Osimertinib, Lazertinib, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,074 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 20
States / cities: Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more

Conditions: Myasthenia Gravis
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: Obesity, Inflammation
Interventions: Grape powder, followed by placebo powder, Placebo powder followed by grape powder; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 20 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Davis, California

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Placebo, AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Inglewood, California • Northridge, California • Pomona, California + 20 more

Conditions: Healthy Adult Females, Healthy Adult Male
Interventions: Lion Mane (Hericium erinaceus) fruiting body extract - Nordic Origin, Lions Mane (Hericium erinaceus) Fruiting body and mycelium, Maltodextrin (Placebo); Dietary Supplement · Other
Lead sponsor: Applied Food Sciences Inc.; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid; Biological · Other · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more

Conditions: Anemia, Sickle Cell
Interventions: Arginine, Placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 5 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 17
States / cities: Oakland, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: Heart Failure, Acute Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 5,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 82
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more

Conditions: Tendinopathy
Interventions: Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy; Drug · Other · Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Gait, Unsteady, Multiple Sclerosis
Interventions: Body-weight supported treadmill training +/- Lokomat assistance, Usual Care - no active intervention; Other
Lead sponsor: Mount Sinai Rehabilitation Hospital; Other
Eligibility: 25 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sunburn
Interventions: oxytocin, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Traumatic Brain Injury
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Congenital Heart Disease in Children
Interventions: Continuous ketorolac; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 3 Months to 59 Months
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cardiac Surgery, Cardiopulmonary Bypass
Interventions: AT-III (Human), Placebo; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 41
States / cities: Orange, California • San Francisco, California • Stanford, California + 36 more

Conditions: Diabetes Mellitus
Interventions: Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dermatitis, Allergic Contact
Interventions: rHuPH20, Placebo; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Michigan City, Indiana

Search by objective public record fields.

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Preventing Urinary Tract Infection Post-Surgery

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Early Treatment With Dexamethasone in Mild Acute Pancreatitis

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

Lokomat Treadmill Training Effects on MS Gait

A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis